Insider Buying: Vectura Group PLC (VEC) Insider Purchases 135 Shares of Stock
Vectura Group PLC (LON:VEC) insider Andrew Derodra purchased 135 shares of the stock in a transaction on Friday, August 4th. The stock was acquired at an average cost of GBX 111 ($1.45) per share, with a total value of £149.85 ($195.14).
Andrew Derodra also recently made the following trade(s):
- On Tuesday, June 6th, Andrew Derodra purchased 135 shares of Vectura Group PLC stock. The stock was acquired at an average cost of GBX 111 ($1.45) per share, with a total value of £149.85 ($195.14).
Vectura Group PLC (LON:VEC) traded up 0.09% during midday trading on Monday, hitting GBX 112.10. The company had a trading volume of 550,103 shares. The firm has a 50-day moving average price of GBX 113.51 and a 200-day moving average price of GBX 132.96. Vectura Group PLC has a 12 month low of GBX 109.50 and a 12 month high of GBX 166.97. The company’s market cap is GBX 759.65 million.
Several equities research analysts have weighed in on VEC shares. Royal Bank Of Canada downgraded Vectura Group PLC to an “underperform” rating in a report on Tuesday, April 25th. N+1 Singer downgraded Vectura Group PLC to a “sell” rating in a report on Monday, April 24th. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 225 ($2.93) target price on shares of Vectura Group PLC in a report on Friday, May 5th. J P Morgan Chase & Co decreased their target price on Vectura Group PLC from GBX 240 ($3.13) to GBX 210 ($2.73) and set an “overweight” rating for the company in a report on Friday, May 12th. Finally, Peel Hunt reaffirmed a “hold” rating and set a GBX 160 ($2.08) target price on shares of Vectura Group PLC in a report on Thursday, June 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of GBX 210.13 ($2.74).
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.